Journal: Cancers

Article Title: The Combined Inhibition of Autophagy and Diacylglycerol Acyltransferase-Mediated Lipid Droplet Biogenesis Induces Cancer Cell Death during Acute Amino Acid Starvation.

doi: 10.3390/cancers15194857

Figure Lengend Snippet: Figure 3. Inhibition of autophagy through ATG5 depletion impairs amino-acid-starvation-induced LD accumulation. (A) Microscopic images showing LD abundance in control and ATG5-deficient HeLa cells during starvation in amino acid (AA)-free medium. (B,C) Changes in the number of small LDs (≤0.41 µm) and large LDs/cell (>0.41 µm) and in the LD diameter in control and ATG5-deficient HeLa cells at 3, 6, and 12 h of starvation in AA-free medium. (D) LC3 puncta and LD abundance in control and ATG5-deficient HeLa cells during starvation in AA-free and in serum-free medium. (E,F) ATG5 protein levels and LC3-II turnover in starving control and ATG5-deficient HeLa (E) and MDA-MB-231 (F) cells in the presence and absence of BafA1, CQ, or 100 µM Rapamycin (Rap).

Article Snippet: Autophagy inhibitors bafilomycin A1 (BafA1), rapamycin (Rap), and 3-methyladenine (3-MA) were from Cayman (Ann Arbor, MI, USA), T863 (DGAT1 inhibitor), PF-06424439 (DGAT2 inhibitor), essentially fatty acid-free (EFAF) bovine serum albumin (BSA) (cat. no. A7511), and Nile Red from Sigma-Aldrich (St. Louis, MO, USA). β-actin antibodies (cat. no. NB600-532) were purchased from Novus Biologicals (Cambridge, UK), LC3 (cat. no. #2775), ATG5 (cat. no. #12994), and ATGL (cat. no. #2138) antibodies from Cell Signaling (Danvers, MA, USA), and horseradish-peroxidase-labelled secondary antibodies from Jackson ImmunoResearch Laboratories (West Grove, PA, USA).

Techniques: Inhibition, Control

Journal: Cancers

Article Title: The Combined Inhibition of Autophagy and Diacylglycerol Acyltransferase-Mediated Lipid Droplet Biogenesis Induces Cancer Cell Death during Acute Amino Acid Starvation.

doi: 10.3390/cancers15194857

Figure Lengend Snippet: Figure 5. Inhibition of autophagy and DGAT-mediated LD biogenesis increase HeLa cell death, but do not affect MDA-MB-231 cell viability during acute amino acid starvation. (A,B) Cell death rates in serum- or amino acid (AA)-starved HeLa- (A) and MDA-MB-231 (B) cells treated with autophagy inhibitors BafA1 and CQ. (C) Cell death rates in AA-starved control and ATG5-deficient HeLa- and

Article Snippet: Autophagy inhibitors bafilomycin A1 (BafA1), rapamycin (Rap), and 3-methyladenine (3-MA) were from Cayman (Ann Arbor, MI, USA), T863 (DGAT1 inhibitor), PF-06424439 (DGAT2 inhibitor), essentially fatty acid-free (EFAF) bovine serum albumin (BSA) (cat. no. A7511), and Nile Red from Sigma-Aldrich (St. Louis, MO, USA). β-actin antibodies (cat. no. NB600-532) were purchased from Novus Biologicals (Cambridge, UK), LC3 (cat. no. #2775), ATG5 (cat. no. #12994), and ATGL (cat. no. #2138) antibodies from Cell Signaling (Danvers, MA, USA), and horseradish-peroxidase-labelled secondary antibodies from Jackson ImmunoResearch Laboratories (West Grove, PA, USA).

Techniques: Inhibition, Control